North America

Tue
29
Jan

Marijuana stocks rise after Organigram doubles revenue forecast

Recreational pot sales are off to a strong start for Organigram Holdings Inc., and Chief Executive Greg Engel said he expect sales to double in the first full quarter of legal marijuana sales in Canada.

Organigram’s strong results suggest that other cannabis companies could generate the kind of sales that led to swollen market capitalizations across the sector — if they can overcome issues that have been plaguing the industry in Canada. Over the past year, licensed cannabis producers in Canada have struggled with crop failures, licensing challenges and lower-than-expected cannabis yields as they attempt to reshape a sector that was outlawed for nearly a century in Canada.

Tue
29
Jan

Cannara Biotech to enter the U.S. hemp-CBD market with launch of online e-commerce platform

Montreal-headquartered Cannara Biotech Inc. plans to enter the U.S. hemp-CBD market, through a subsidiary, with an online e-commerce platform called shopCBD.com.

“The new e-commerce platform will showcase retail products from hemp-CBD manufacturers for the U.S. consumer market,” states a press release from Cannara Biotech, a vertically integrated cannabis company focused on cannabis-infused products.

Tue
29
Jan

How to deal with the medical cannabis dilemma

There is a general consensus that cannabis should be treated like any other medicinal plant. However, it is not quite clear what this means, since this standard may be interpreted differently with serious consequences for patients. Cannabis is not a medicinal plant like any other. This causes a dilemma that poses problems to courts confronted with illegal self-medication and lawmakers, who want to balance possible benefits for patients and protection with potential harms.

Why cannabis medicines are not medications like any other

There are two major reasons why cannabis is not a medicinal drug like any other.

Tue
29
Jan

Organigram locks up supply of hemp-derived CBD through agreement with N.B. research company

Organigram Holdings Inc., the parent company of Organigram Inc., has entered into an agreement with 1812 Hemp to secure supply and support research and development on the genetic improvement of hemp through traditional plant breeding methods.

Tue
29
Jan

High hopes for the cannabis tourism industry

Cannabis tourism has come along way. The idea of being "hotboxed" on a smoke-filled bus with a stripper pole and a group of strangers is far from the ideal experience for both new and seasoned cannabis users. As the cannabis industry grows so does the expectations for high-quality goods and services -- and the possible eradication of hotboxing altogether.

Tue
29
Jan

What fearmongering about pot tells you about mainstream marijuana coverage

For the first time in decades, federal marijuana legalization seems possible in the foreseeable future. Given the wave of states’ legalizing cannabis through ballot initiatives, the grudging acceptance of its “inevitability” by the Food and Drug Administration, and the number of Democratic candidates slipping it into their campaign agendas, cannabis advocates are finally seeing years of activism come to fruition on a nationwide level.

Proponents bank on positive outcomes like a reduction in both the size and racial disparities of our country’s prison population; more latitude for researchers to study marijuana’s value as a medicine; and ready access to medical marijuana for anyone who needs it.

Tue
29
Jan

Cannabis suppositories are a new doctor-approved trend in medical marijuana

Smoking is bad for your lungs, vaping requires expensive equipment, and marijuana edibles are hard to dose. That leaves one option: the back door. The prudish among us may cringe at the idea of slipping cannabis into our anuses to achieve relief from Crohn’s disease, chronic pain, or epilepsy, but doctors and the marijuana industry are increasingly advocating for cannabis extract suppositories.

Mon
28
Jan

The news that sent marijuana stock Canopy Growth soaring

A lot is going right for Canopy Growth (NYSE:CGC) lately. The market-share-leading Canadian cannabis company is poised for significant sales growth in 2019 following the opening of Canada's recreational marijuana market last October. And in January, Canopy Growth responded to news that hemp is being removed from the controlled-substances list with plans to leap into the U.S. market via a planned hemp innovation park in New York State.

Mon
28
Jan

Could Aurora Cannabis be a millionaire-maker stock?

Let's cut to the chase. Yes, Aurora Cannabis (NYSE:ACB) could be a millionaire-maker stock. Given a large enough initial investment and enough time, many stocks -- including Aurora -- could generate returns of $1 million or more.

The real question, though, is whether an investor buying a reasonable stake in Aurora Cannabis has a realistic chance of becoming a millionaire from this initial investment over a period of time that's not ridiculously long. For example, could a $10,000 initial investment in Aurora turn into $1 million within 25 years?

Mon
28
Jan

Cannabis labs find deadly chemical in certain vape cartridges

Portable and discreet vape pens are a very profitable segment of legal recreational cannabis markets, writes Calvin Hughes. For people who don't want to deal with the unpredictability of edibles but also don't want to smell like they just smoked a joint, these pocket-sized vaporizers are very popular, but people might start going back to joints and pot cookies after news broke that some vape cartridges contain potentially dangerous levels of lead.

Pages

Subscribe to RSS - North America